Quercetin

Quercetin

SCHEMBL6440211

O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12.O=c1cc(-c2ccccc2)oc2ccccc12

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.68
KMT2A Q03164 12/20 0.68
KDM4E B2RXH2 11/20 0.68
CYP3A4 P08684 10/20 0.68
HSD17B10 Q99714 10/20 0.68
MAPT P10636 10/20 0.68
CYP1A2 P05177 9/20 0.68
CYP2C9 P11712 8/20 0.68
FTO Q9C0B1 8/20 0.68
CYP1A1 P04798 8/20 0.68
CYP1B1 Q16678 8/20 0.68
ALOX15 P16050 7/20 0.68
RECQL P46063 7/20 0.68
CYP2D6 P10635 7/20 0.68
CYP2C19 P33261 7/20 0.68
XDH P47989 7/20 0.68
POLH Q9Y253 7/20 0.68
IP6K2 Q9UHH9 7/20 0.68
TP53 P04637 6/20 0.68
HIF1A Q16665 6/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kaempferol SCHEMBL28180527 0.92 ABCB1 (0.69) MEN1KMT2AKDM4ECYP3A4HSD17B10
Quercetin SCHEMBL4303275 0.91 MEN1 (0.74) MEN1KMT2AKDM4ECYP3A4HSD17B10
Quercetin SCHEMBL10877423 0.90 MEN1 (0.65) MEN1KMT2AKDM4ECYP3A4HSD17B10
Quercetin SCHEMBL111510 0.89 MEN1 (0.76) MEN1KMT2AKDM4ECYP3A4HSD17B10
Luteolin SCHEMBL4918304 0.88 CYP3A4 (0.66) MEN1KMT2AKDM4ECYP3A4HSD17B10
Quercetin SCHEMBL18555282 0.88 KMT2A (0.68) MEN1KMT2AKDM4ECYP3A4HSD17B10
Morin SCHEMBL6043175 0.88 FTO (0.65) MEN1KMT2AKDM4ECYP3A4HSD17B10
Luteolin SCHEMBL8161993 0.88 MEN1 (0.72) MEN1KMT2AKDM4ECYP3A4HSD17B10
Luteolin SCHEMBL1229732 0.87 POLH (0.75) MEN1KMT2AKDM4ECYP3A4HSD17B10
Luteolin SCHEMBL15271260 0.87 POLH (0.75) MEN1KMT2AKDM4ECYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113229505-A Anti-aging collagen peptide and preparation method thereof 杭州葆瑞生物科技有限公司 2021-08-10 CN claimed
CN-116998685-A Preparation method of haw extract 福建红果宝健康产业有限公司 2023-11-07 CN disclosed
CN-116920019-A Application of haw extract in preparing medicine for treating constipation 福建红果宝健康产业有限公司 2023-10-24 CN disclosed
CN-116920018-A Hawthorn fruit extract and application thereof 福建红果宝健康产业有限公司 2023-10-24 CN disclosed
CN-116898906-A Application of haw extract in preparing medicine for treating cancer pain 福建红果宝健康产业有限公司 2023-10-20 CN disclosed
CN-116099467-A Quercetin microcapsule and preparation method thereof 吉林大学 2023-05-12 CN disclosed
CN-113229505-A Anti-aging collagen peptide and preparation method thereof 杭州葆瑞生物科技有限公司 2021-08-10 CN disclosed
CN-106102757-B Anti-neuritis and protective compounds in yarrow 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 2021-06-25 CN disclosed
CN-106811440-B Method for separating and culturing buffalo mammary epithelial cells from buffalo milk 广西壮族自治区水牛研究所 2020-09-15 CN disclosed
CN-111093642-A Expression of PD-L1 inhibition and expression of PD1 enhancement IN原料公司 2020-05-01 CN disclosed
US-20040235965-A1 Utilization of rutins and aescins in the treatment of circulatory disturbances of the ear BRENCH AG (DE) 2004-11-25 US disclosed
US-5922316-A ADDING GENE-INDUCING FLAVONOID MCGILL UNIVERSITY (CA) 1999-07-13 US disclosed
US-5872223-A TREATING CANCERS AND AUTOIMMUNE DISEASES IN HUMANS ARE PROVIDED WHICH COMPRISE A TYROSINE KINASE INHIBITOR LINKED TO A LIGAND TARGETING A CELL SURFACE RECEPTOR WHICH ARE SPECIFICALLY CAPABLE OF INHIBITING RECEPTOR ASSOCIATED REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1999-02-16 US disclosed
EP-0776338-B1 IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS UNIV MINNESOTA (US) 1998-12-09 EP disclosed
EP-0776338-A1 IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1997-06-04 EP disclosed
US-5587459-A LINKED TO A LIGAND TARGETING A CELL SURFACE RECEPTOR; FOR TREATING CANCERS AND AUTOIMMUNE DISEASES REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1996-12-24 US disclosed
WO-1996006116-A9 IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS 1996-03-28 WO disclosed
WO-1996006116-A1 IMMUNOCONJUGATES COMPRISING TYROSINE KINASE INHIBITORS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1996-02-29 WO disclosed
US-5141745-A Gene expression THE LUBRIZOL CORPORATION (US) 1992-08-25 US disclosed
EP-0245931-A2 Nodulation inducing factors LUBRIZOL GENETICS INC. (US) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235965-A1 Utilization of rutins and aescins in the treatment of circulatory disturbances of the ear ECHS1, CIAPIN1, WFS1 MEN1 1045/4885KMT2A 4476/4885KDM4E 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.